Skip to content

Measurement of thickness of black layer of eye after refractive surgery

Changes In Epithelial Thickness Following Local Application Of Mitomycin -C After Photorefractive Keratectomy- A prospective Study - MMC study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2019/02/017595
Enrollment
86
Registered
2019-02-12
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H183- Changes of corneal membranes

Interventions

None listed

Sponsors

Dr Lakhani Basitali Habibbhai
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Candidate should have a myopia between (-1.5 to 10 D) and astigmatism up to (-4D). 2. With documented stability of refraction, as demonstrated by a change of less than or equal to 1 D of myopia and (-0.5 D) of astigmatism at least12 months in the preoperative examination. 3. Candidates with corneal thickness of 500μ and less, Minimal corneal thickness of 470μ and above on orbscan and calculated residual stromal bed of minimum 300μ.

Exclusion criteria

Exclusion criteria: 1. Unstable refractive error for 2. Insufficient corneal thickness for the proposed ablation depth. 3. Any other refractive error other than simple myopia and myopic astigmatism. 4. Abnormalities of the cornea (eg. Keratoconus or other corneal ectasia, thinning, edema, interstitial keratitis, extensive vascularization, corneal opacity, epithelial dystrophy etc). 5. Patient undergoing PRK for previous complication of LASIK or FEMTOLASIK. 6. Uncontrolled external disease of the eye (eg. Dry eye, atopy, and blepharitis). 7. Previous history of vitreoretinal surgery or any other intra ocular and extra ocular surgery. 8. Age group less than 21 years and more than 40 years. 9. Monocular patient. 10. Patient on any drug treatment which produce dry eye (MAO inhibitors, alpha agonists, beta blockers, thiazide diuretics, NSAIDS). 11. Uncontrolled connective tissue or autoimmune disease. 12. Pregnant or nursing woman.

Design outcomes

Primary

MeasureTime frame
1) Epithelial Thickness Changes Using AS-OCT 2)To Assess UCVA AND BCVATimepoint: 1 year 6 months

Secondary

MeasureTime frame
1)To assess TBUT(tear film break up time) 2)To assess corneal staining score 3)To assess Schirmers ScoreTimepoint: 1 year 6 months

Countries

India

Contacts

Public ContactDr Lakhani Basitali Habibbhai

Aravind Eye Hospital and Postgraduate Institute Of Ophthalmology

drshivan@rediffmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026